Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Frost & Sullivan Recognizes Lifeblood Medical for Its Innovation in Organ Preservation and Development of the Lifor® Solution

Abstract:
Frost & Sullivan is pleased to present the 2008 North American Pharmaceuticals & Biotechnology Emerging Markets Healthcare Innovation Award to Lifeblood Medical.

Frost & Sullivan Recognizes Lifeblood Medical for Its Innovation in Organ Preservation and Development of the Lifor® Solution

Mountain View, CA | Posted on October 27th, 2008

This is in recognition of the company's unique solution technology, which offers a myriad of advantages and has led to the development of Lifor®, a breakthrough product for organ preservation solution. In addition to human organ preservation, Lifeblood Medical's technology has potential for a wide number of applications and presents a unique opportunity for the company to impact multiple emerging healthcare markets.

Current preservation solutions restrict the duration organs remain viable between harvesting and re-implantation. In addition to time, temperature constraints, cost effectiveness, increasing demand, and the need to protect against ischemia reperfusion injury are all characteristics which showcase the need for product and technology improvements in the area of organ preservation solutions.

"With Lifor, Lifeblood Medical has developed a product with capabilities and characteristics that positively differentiate from other organ transplant products both in the market and in visible development," says Frost & Sullivan Research Analyst Barath Shankar Subramanian. "By positioning focus in a high profile and underserved area of organ transplant through a highly innovative and flexible technology, Lifeblood Medical is at the forefront of product innovation in organ transplant and preservation."

A synthetic preservation medium containing cellular nutrients, Lifor is a non-animal protein oxygen and nanoparticle carrier. It can carry oxygen and nutrients to cells and tissues, helping them sustain metabolic processes and stay alive; a critical factor in organ transplantation. In comparison to existing organ preservation solutions that can preserve liver and kidney for 12 hours at hypothermic (below 20º C and typically at about 4º C) temperatures, Lifor offers a three-fold increase of up to 36 hours at room and body temperature - a breaking innovation in a market that serves a critical life-saving need.

Unlike other competing products, Lifor is animal protein and animal serum free, removing the possibility of contamination during cell culturing and preservation. Further, Lifeblood Medical does not use dimethyl sulfoxide (DMSO) in its product. A commonly used chemical in cryopreservation, DMSO is considered to be toxic to cells. Lifeblood has been able to achieve better results through this solution.

"Its innovative technology provides Lifeblood Medical the opportunity to expand its applications beyond organ transplantation and create new niches," notes Subramanian. "Other potential applications that provide Lifeblood Medical the opportunity to expand its position in the marketplace and accelerate its growth include stem cell research, flu vaccines, cancer research, limb preservation, tissue banking, cryopreservation of sperm cells for in vitro fertilization, and as a blood substitute."

Lifeblood Medical's technology offers a non-toxic medium for collection and preservation of stem cells and cryopreservation of cord blood. It has a potential application in the cell-based production of flu vaccines due to the lack of animal products. In cancer research, Lifeblood Medical's solution can help preserve tumor tissue, assisting companies to develop a patient-specific approach towards cancer treatment. Limb preservation can also benefit trauma medicine in both the civilian and military setting. The U.S. Navy is currently investigating Lifeblood Medical's solution technology in this setting.

For developing a solution for a variety of underserved areas of healthcare, and providing a technology platform that could drive innovation and improve medicine, Lifeblood Medical is the worthy recipient of the 2008 North American Frost & Sullivan Healthcare Innovation Award in the pharmaceuticals and biotechnology emerging markets.

Each year, Frost & Sullivan presents this award to the company that has introduced truly innovative products, practices, or ideas to the specified industry or segment. The company's innovative contribution(s) to healthcare make it possible to envision a new level of care in the diagnosis, treatment, and management of disease, leading to better outcomes and quality-of-life for patients. In addition, the company's innovative efforts may also lead to improvements in the tools that clinicians, diagnosticians, researchers, and healthcare administrators have at their disposal to improve quality and efficiency in provision of healthcare services. In the development of its innovative contributions to healthcare, the company has drawn from a substantial body of expertise in the clinical and scientific communities, leading to products, practices, or research and development initiatives that respond directly to the needs and insights expressed by thought leaders in the respective clinical specialties and/or industry segments.

Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Lifeblood Medical

Lifeblood Medical, Inc. (lifebloodmedical.com) is a leading innovator in providing GMP approved, animal-free and toxic-free component solutions for a wide range of applications in multiple healthcare markets. The Company draws upon its proprietary patented technology to address some of the world's most pressing issues in the fields of organ preservation, regenerative medicine and cell therapy. Lifeblood Medical, Inc.'s vision is to continue to develop novel solutions through our ability to preserve every cell in the human body.

####

About Frost & Sullivan


This is in recognition of the company’s unique solution technology, which offers a myriad of advantages and has led to the development of Lifor®, a breakthrough product for organ preservation solution. In addition to human organ preservation, Lifeblood Medical’s technology has potential for a wide number of applications and presents a unique opportunity for the company to impact multiple emerging healthcare markets.

Current preservation solutions restrict the duration organs remain viable between harvesting and re-implantation. In addition to time, temperature constraints, cost effectiveness, increasing demand, and the need to protect against ischemia reperfusion injury are all characteristics which showcase the need for product and technology improvements in the area of organ preservation solutions.

“With Lifor, Lifeblood Medical has developed a product with capabilities and characteristics that positively differentiate from other organ transplant products both in the market and in visible development,” says Frost & Sullivan Research Analyst Barath Shankar Subramanian. “By positioning focus in a high profile and underserved area of organ transplant through a highly innovative and flexible technology, Lifeblood Medical is at the forefront of product innovation in organ transplant and preservation.”

A synthetic preservation medium containing cellular nutrients, Lifor is a non-animal protein oxygen and nanoparticle carrier. It can carry oxygen and nutrients to cells and tissues, helping them sustain metabolic processes and stay alive; a critical factor in organ transplantation. In comparison to existing organ preservation solutions that can preserve liver and kidney for 12 hours at hypothermic (below 20º C and typically at about 4º C) temperatures, Lifor offers a three-fold increase of up to 36 hours at room and body temperature - a breaking innovation in a market that serves a critical life-saving need.

Unlike other competing products, Lifor is animal protein and animal serum free, removing the possibility of contamination during cell culturing and preservation. Further, Lifeblood Medical does not use dimethyl sulfoxide (DMSO) in its product. A commonly used chemical in cryopreservation, DMSO is considered to be toxic to cells. Lifeblood has been able to achieve better results through this solution.

“Its innovative technology provides Lifeblood Medical the opportunity to expand its applications beyond organ transplantation and create new niches,” notes Subramanian. “Other potential applications that provide Lifeblood Medical the opportunity to expand its position in the marketplace and accelerate its growth include stem cell research, flu vaccines, cancer research, limb preservation, tissue banking, cryopreservation of sperm cells for in vitro fertilization, and as a blood substitute.”

Lifeblood Medical’s technology offers a non-toxic medium for collection and preservation of stem cells and cryopreservation of cord blood. It has a potential application in the cell-based production of flu vaccines due to the lack of animal products. In cancer research, Lifeblood Medical’s solution can help preserve tumor tissue, assisting companies to develop a patient-specific approach towards cancer treatment. Limb preservation can also benefit trauma medicine in both the civilian and military setting. The U.S. Navy is currently investigating Lifeblood Medical’s solution technology in this setting.

For developing a solution for a variety of underserved areas of healthcare, and providing a technology platform that could drive innovation and improve medicine, Lifeblood Medical is the worthy recipient of the 2008 North American Frost & Sullivan Healthcare Innovation Award in the pharmaceuticals and biotechnology emerging markets.

Each year, Frost & Sullivan presents this award to the company that has introduced truly innovative products, practices, or ideas to the specified industry or segment. The company's innovative contribution(s) to healthcare make it possible to envision a new level of care in the diagnosis, treatment, and management of disease, leading to better outcomes and quality-of-life for patients. In addition, the company's innovative efforts may also lead to improvements in the tools that clinicians, diagnosticians, researchers, and healthcare administrators have at their disposal to improve quality and efficiency in provision of healthcare services. In the development of its innovative contributions to healthcare, the company has drawn from a substantial body of expertise in the clinical and scientific communities, leading to products, practices, or research and development initiatives that respond directly to the needs and insights expressed by thought leaders in the respective clinical specialties and/or industry segments.

Frost & Sullivan’s Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Lifeblood Medical

Lifeblood Medical, Inc. (lifebloodmedical.com) is a leading innovator in providing GMP approved, animal-free and toxic-free component solutions for a wide range of applications in multiple healthcare markets. The Company draws upon its proprietary patented technology to address some of the world's most pressing issues in the fields of organ preservation, regenerative medicine and cell therapy. Lifeblood Medical, Inc.'s vision is to continue to develop novel solutions through our ability to preserve every cell in the human body.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

For more information, please click here

Contacts:
Jake Wengroff
210.247.3806
jake.wengroff[.]frost.com

Copyright © Newswire Today

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Characterizing inkjet inks: Malvern Instruments presents new rheological research April 23rd, 2014

NanoSafe, Inc. announces the addition of the Labconco Protector® Glove Box to its NanoSafe Tested™ registry April 23rd, 2014

Study finds long-term survival of human neural stem cells transplanted into primate brain April 23rd, 2014

High-Performance, Low-Cost Ultracapacitors Built with Graphene and Carbon Nanotubes: Future devices based on technology could bridge gap between batteries and conventional capacitors in portable electronics and hybrid electric vehicles April 23rd, 2014

Nanomedicine

QuantuMDx announce prototype handheld lab for 15 minute malaria diagnosis and drug resistance testing April 23rd, 2014

Study finds long-term survival of human neural stem cells transplanted into primate brain April 23rd, 2014

Cloaked DNA nanodevices survive pilot mission: Successful foray opens door to virus-like DNA nanodevices that could diagnose diseased tissues and manufacture drugs to treat them April 22nd, 2014

Berkeley Lab Researchers Demonstrate First Size-based Chromatography Technique for the Study of Living Cells April 22nd, 2014

Announcements

Characterizing inkjet inks: Malvern Instruments presents new rheological research April 23rd, 2014

NanoSafe, Inc. announces the addition of the Labconco Protector® Glove Box to its NanoSafe Tested™ registry April 23rd, 2014

Study finds long-term survival of human neural stem cells transplanted into primate brain April 23rd, 2014

High-Performance, Low-Cost Ultracapacitors Built with Graphene and Carbon Nanotubes: Future devices based on technology could bridge gap between batteries and conventional capacitors in portable electronics and hybrid electric vehicles April 23rd, 2014

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

National Space Society Congratulates SpaceX on the Success of CRS-3 and the First Flight of the Falcon 9R April 22nd, 2014

Energy Research Facility Construction Project at Brookhaven Lab Wins U.S. Energy Secretary's Achievement Award April 16th, 2014

IDTechEx Printed Electronics Europe 2014 Award Winners April 1st, 2014

Dais Analytic Wins SBIR Grant: Dais Analytic Receives US Army Small Business Innovation Research Grant to Further Its Demonstrated Successes in Cleaning Most Forms of Wastewater March 28th, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE